NBY Company Profile and Key Details

Q: Who are the executives of NBY?

Dr. Jeffrey Kunin M.D.Pres of DERMAdoctorMr. Andrew D. JonesChief Financial Officer & TreasurerMr. Justin M. Hall Esq.Pres, Chief Executive Officer, Gen. Counsel, Chief Compliance Officer, Corporation Sec. & DirectorMr. Tommy LawController, Interim Chief Financial Officer & TreasurerDr. Audrey Kunin M.D.Chief Product Officer

AMEX : NBY

NovaBay Pharmaceuticals

$1.47

-0.4801-24.62%

At Close 4:00 PM

Not Actively Trading

70.33

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

NovaBay Pharmaceuticals, Inc. (NBY) stock declined over -24.62%, trading at $1.47 on AMEX, down from the previous close of $1.95. The stock opened at $1.47, fluctuating between $1.47 and $1.47 in the recent session.

Stock Snapshot

1.95

Prev. Close

39.14M

Market Cap

1.4699

Day Low

-0.051575438596491226

P/E Ratio

-28.5

EPS (TTM)

-0.36

Cash Flow per Share

1.47

Open

26.63M

Number of Shares

1.4699

Day High

100.03%

Free Float in %

0.3

Book Value

86.83K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 22, 2026	1.54	1.54	1.41	1.41	4.66M
Apr 02, 2026	1.58	1.98	1.57	1.95	623.93K
Apr 01, 2026	1.51	1.69	1.49	1.59	211.47K
Mar 31, 2026	1.44	1.52	1.37	1.49	246.43K
Mar 30, 2026	1.44	1.50	1.33	1.35	254.79K
Mar 27, 2026	1.53	1.60	1.42	1.50	224.32K
Mar 25, 2026	1.63	1.65	1.40	1.42	377.27K
Mar 24, 2026	1.40	1.75	1.27	1.50	1.2M
Mar 23, 2026	1.19	1.49	1.13	1.38	1.06M
Mar 20, 2026	1.22	1.25	1.16	1.16	128.65K
Mar 19, 2026	1.25	1.28	1.15	1.22	247.3K
Mar 18, 2026	1.30	1.36	1.26	1.28	223.33K
Mar 17, 2026	1.43	1.46	1.26	1.36	430.63K
Mar 16, 2026	1.23	1.85	1.22	1.45	5.46M
Mar 13, 2026	1.24	1.28	1.14	1.21	182.54K
Mar 12, 2026	1.25	1.30	1.19	1.27	215.39K
Mar 11, 2026	1.24	1.36	1.20	1.27	240.65K
Mar 10, 2026	1.22	1.30	1.14	1.26	320.35K
Mar 09, 2026	1.38	1.38	1.11	1.24	501.42K
Mar 06, 2026	1.50	1.60	1.35	1.39	1.29M

Contact Details

EmeryVille, CA 94608

United States

https://novabay.com 510 899 8800

About Company

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.

Stock Peers

PTHS

-0.84-3.00%

Pelthos Therapeutics Inc.$27.16 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.13+1.84%

NeurAxis, Inc.$7.21 ARMP

-0.27-5.29%

Armata Pharmaceuticals, Inc.$4.83 CANF

0.02+0.62%

Can-Fite BioPharma Ltd.$3.27 PLX

-0.01-0.42%

Protalix BioTherapeutics, Inc.$2.37 SER

0.23+11.50%

Serina Therapeutics, Inc.$2.23 OSTX

0.26+17.81%

OS Therapies Incorporated$1.72 NNVC

0.06+3.87%

NanoViricides, Inc.$1.61

Company Overview

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) closed at $1.47 USD, losing -$0.48 (-24.62%) from the previous close of $1.95. The stock is currently mid-range between its 52-week high and low $1.11 and $99.75. With a market capitalization of about $39.14 million, NovaBay Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.16). Key stats such as the average daily volume over the past year has been around 552.07 thousand shares, volume is running light vs its 52-week average. Headquartered in EmeryVille, CA, NovaBay Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Kazley, the company employs approximately 13 people and listed since October 26, 2007. NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -60.51%, SMA50 -93.13%, SMA200 -82.7%). The stock’s 14-day RSI is 34.29 (weak momentum), while the ATR of 3.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.45% below its high and over 3.33% above its low.

Valuation Metrics

NovaBay Pharmaceuticals, Inc. trades at a P/E ratio of 0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 15.89 and a price-to-book ratio of 0.28 suggesting the stock is closer to book value. The P/FCF stands at -4.41, also below market averages.

Dividend & Fair Value

NovaBay Pharmaceuticals, Inc. last paid a dividend of 0.8 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.23. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

NovaBay Pharmaceuticals, Inc. generated EPS of -$7.43 over the past year. Five-year average earnings growth is 66.43%. The latest quarter delivered EPS of $21.23. The next quarter is forecast at $nan. Next year's EPS is expected at $68.40. NovaBay Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 01, 2026, missed forecasts by -2223.0%. The prior quarter beat by 369.0%. Over the last six quarters, Apple has recorded several small beats. These include 13741.67% in April 01, 2025.

Shareholding & Insider Activity

NovaBay Pharmaceuticals, Inc. has 26.12 million shares outstanding. The public float is 2.05 million shares, elevated short interest at 22.57% of float. This equals 767.85 thousand shares. The short ratio is 2.04 days. Institutional investors hold 21.28% of the float. Insiders own 0.02%. Pioneer Pharma (Hong Kong) Co Ltd holds 5.19 million shares, Pioneer Pharma (Singapore) Pte. Ltd. has 4.53 million shares and Fu Jian Ping has 4.00 million shares.

Financial & Profitability Overview

Over the trailing twelve months, NovaBay Pharmaceuticals generated $14.73M in revenue, or $3.49 per share. Gross margin was 53.61%, operating margin -33.97%, and net profit margin -65.46%. Returns are negative, with ROA at -106.71% and ROE at -290.89%.
On valuation metrics, NovaBay Pharmaceuticals trades at a P/E of 0.09, P/S of 15.89 and P/B of 0.28. The current ratio is 5.33 and quick ratio is 5.33. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -18999.21 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -13.92.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, NovaBay Pharmaceuticals posted revenue of $14.73M, down slightly from $14.40M in the prior quarter. Gross profit was $7.90M (margin 53.61%). Operating income was - $5.00M (margin -34.0%). Net income was- $9.64M (EPS - $2.29).
The company ended the quarter with $3.13M in cash and short-term investments, a total debt of $2.74M, and net debt of - $390.00K. Total assets were $9.03M, with equity of $3.31M. Financials further reflected weakness, with operating cash flow of - $4.31M, free cash flow of - $4.33M, and capital expenditures of - $19.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that NovaBay Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -29.08%, with price expected at $1.00 by June 05, 2026, within a range of $0.46 to $1.57 3-Month Outlook: Projected rise of 2363.83%, reaching $34.74 by August 20, 2026, with a range of $33.70 to $35.78. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 21, 2027, within a range of $0.00 to $0.00.

Key Takeaways

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) shares are up 15.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NovaBay Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 0.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.63, suggesting 228.37% upside. Our AI forecast model points to short-term weakness (-29.08% over two weeks), a medium-term rise (2363.83% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current NovaBay Pharmaceuticals, Inc. (NBY) stock price?

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) stock price is $1.47 in the last trading session. During the trading session, NBY stock reached the peak price of $1.47 while $1.47 was the lowest point it dropped to. The percentage change in NBY stock occurred in the recent session was -24.62% while the dollar amount for the price change in NBY stock was - $0.48.

NBY's industry and sector of operation?

The AMEX listed NBY is part of Biotechnology industry that operates in the broader Healthcare sector. NovaBay Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NBY?

Dr. Jeffrey Kunin M.D.
Pres of DERMAdoctor
Mr. Andrew D. Jones
Chief Financial Officer & Treasurer
Mr. Justin M. Hall Esq.
Pres, Chief Executive Officer, Gen. Counsel, Chief Compliance Officer, Corporation Sec. & Director
Mr. Tommy Law
Controller, Interim Chief Financial Officer & Treasurer
Dr. Audrey Kunin M.D.
Chief Product Officer

How NBY did perform over past 52-week?

NBY's closing price is 32.42% higher than its 52-week low of $1.11 where as its distance from 52-week high of $99.75 is -98.53%.

How many employees does NBY have?

Number of NBY employees currently stands at 13.

Link for NBY official website?

Official Website of NBY is: https://novabay.com

How do I contact NBY?

NBY could be contacted at phone 510 899 8800 and can also be accessed through its website. NBY operates from 2000 Powell Street, EmeryVille, CA 94608, United States.

How many shares of NBY are traded daily?

NBY stock volume for the day was 86.83K shares. The average number of NBY shares traded daily for last 3 months was 552.07K.

What is the market cap of NBY currently?

The market value of NBY currently stands at $39.14M with its latest stock price at $1.47 and 26.63M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	13
Beta	0.16
Sales or Revenue	$14.73M
5Y Sales Change%	-0.919%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NBY Company Profile and Key Details

NovaBay Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways